Bufuralol Hydrochloride: A Non-Selective β-Adrenergic Receptor Antagonist for Cardiovascular Pharmacology Research

Executive Summary: Bufuralol hydrochloride (CAS 60398-91-6) is a crystalline, small molecule non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, widely employed in cardiovascular pharmacology research (APExBIO). It induces tachycardia in animal models with catecholamine depletion, confirming its partial agonist profile (Saito et al., 2025). The compound demonstrates membrane-stabilizing effects in vitro and inhibits exercise-induced heart rate elevation for extended periods, comparable to propranolol. It is highly soluble in ethanol (up to 15 mg/ml), DMSO (10 mg/ml), and dimethyl formamide (15 mg/ml), and requires storage at −20°C for stability. Its integration into hiPSC-derived organoid models addresses translational challenges in β-adrenergic modulation studies and drug metabolism research (DOI).

Biological Rationale

β-adrenergic receptors (β-ARs) are pivotal in cardiovascular physiology, mediating the effects of catecholamines such as norepinephrine and epinephrine on heart rate, contractility, and vascular tone. Non-selective β-adrenergic receptor antagonists, like Bufuralol hydrochloride, block both β1 and β2 receptor subtypes, influencing cardiac output and peripheral vascular resistance. These antagonists are used for investigating the pathophysiology of arrhythmias, hypertension, and other cardiovascular diseases.

Traditional animal models and immortalized cell lines (e.g., Caco-2) have limitations in recapitulating human-specific drug metabolism, especially for orally administered agents (Saito et al., 2025). Human induced pluripotent stem cell (hiPSC)-derived organoids, particularly intestinal models, now provide a more accurate platform for pharmacokinetic studies, including the assessment of β-adrenergic modulators like Bufuralol hydrochloride. These organoids express relevant CYP450 enzymes and transporter activities, critical for evaluating drug absorption, metabolism, and excretion.

Mechanism of Action of Bufuralol hydrochloride

Bufuralol hydrochloride is classified as a non-selective β-adrenergic receptor blocker with partial intrinsic sympathomimetic activity. It binds to both β1 and β2 adrenoceptors, competitively inhibiting the binding of endogenous catecholamines. This antagonism results in decreased heart rate, reduced myocardial contractility, and lower blood pressure under normal physiological conditions.

Unlike pure antagonists, Bufuralol hydrochloride exhibits partial agonist activity—demonstrated by its capacity to induce tachycardia in catecholamine-depleted animal models. This effect is attributable to low-level receptor activation even in the absence of endogenous agonists. Additionally, in vitro studies have shown that Bufuralol hydrochloride stabilizes cellular membranes, further modulating cardiac excitability and arrhythmia threshold (APExBIO).

Evidence & Benchmarks

• Bufuralol hydrochloride induces tachycardia in catecholamine-depleted animal models, confirming partial intrinsic sympathomimetic activity (Saito et al., 2025).
• It inhibits exercise-induced heart rate elevation with a duration of effect comparable to propranolol in human subjects (Saito et al., 2025).
• Membrane-stabilizing effects are observed in vitro, suggesting utility as an antiarrhythmic probe (APExBIO).
• hiPSC-derived intestinal organoids accurately recapitulate drug-metabolizing enzyme expression and transporter function relevant to Bufuralol hydrochloride pharmacokinetics (Saito et al., 2025).
• Bufuralol hydrochloride exhibits high solubility in ethanol (up to 15 mg/ml), DMSO (10 mg/ml), and DMF (15 mg/ml) under laboratory conditions (20–25°C) (APExBIO).

For a broader context on translational beta-adrenoceptor signaling, see this article which focuses on molecular pharmacology; the current article extends those insights to hiPSC-derived organoid integration.

For a discussion of advanced β-adrenergic blockade in human in vitro models, see here; this article provides updated benchmarks for Bufuralol hydrochloride using new organoid protocols.

Applications, Limits & Misconceptions

Bufuralol hydrochloride is widely used in cardiovascular pharmacology research, especially for probing beta-adrenoceptor signaling pathways and evaluating antiarrhythmic drug effects. It serves as a reference compound in studies of β-adrenergic modulation, both in vivo and in vitro, including cutting-edge organoid-based pharmacokinetic workflows.

Integration with hiPSC-derived organoid models enables precise modeling of human drug absorption and metabolism, addressing species-specific differences that limit the utility of animal models (Saito et al., 2025). However, certain limitations and misconceptions persist.

Common Pitfalls or Misconceptions

• Not a selective β1 antagonist: Bufuralol hydrochloride blocks both β1 and β2 receptors non-selectively; it is unsuitable for studies requiring β1 specificity.
• Partial agonist effects: The intrinsic sympathomimetic activity can confound interpretation in settings where pure antagonism is required.
• Not suitable for long-term solution storage: Bufuralol hydrochloride solutions degrade over time and should be prepared fresh and used promptly (APExBIO).
• Animal model limitations: Rodent studies may not accurately predict human pharmacokinetics due to species differences in CYP enzyme expression (Saito et al., 2025).
• No direct therapeutic use: While valuable as a research tool, Bufuralol hydrochloride is not approved for clinical therapy in humans.

Workflow Integration & Parameters

Bufuralol hydrochloride (C5043) from APExBIO is supplied as a crystalline powder. For typical in vitro studies, stock solutions are prepared in ethanol (up to 15 mg/ml), DMSO (10 mg/ml), or DMF (15 mg/ml). Working solutions should be freshly prepared and used immediately to avoid degradation. Storage at −20°C is required for optimal stability of the solid compound.

In pharmacokinetic assays using hiPSC-derived intestinal organoids, Bufuralol hydrochloride is applied to monolayer cultures of enterocyte-like cells. These organoids express CYP3A4 and relevant transporters, enabling accurate modeling of human drug absorption and metabolism (Saito et al., 2025).

For advanced β-adrenergic modulation studies, see this resource; the present article clarifies the integration of Bufuralol hydrochloride into organoid-based workflows, emphasizing updated protocols and storage parameters.

Conclusion & Outlook

Bufuralol hydrochloride is a robust, well-characterized non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Its use in cardiovascular pharmacology research is supported by extensive experimental evidence and validated protocols. Integration with hiPSC-derived organoid models represents a significant advance in translational β-adrenergic modulation studies, overcoming species barriers and improving predictive power for human drug responses. For standardized, reproducible research outcomes, strict adherence to storage and preparation guidelines is essential. The C5043 kit from APExBIO ensures high-quality, reliable performance for diverse experimental applications.